# Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

> **NCT00934544** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 219 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Best Available Therapy (BAT)

## Key facts

- **NCT ID:** NCT00934544
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-01
- **Primary completion:** 2015-03-04
- **Final completion:** 2015-03-04
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2019-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00934544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00934544, "Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00934544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*